Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Cardiac deaths increase significantly during compound heatwaves-heatwaves where temperatures are elevated both during the day and overnight-according to a new study in JACC, the flagship journal ...

There are valuation issues, however, even after the significant decline in the stock price following the loss of its ability to compound semaglutide. Before making an investment in the stock ...

I think STRIDE helps us here because among the various drugs for diabetes, if your patient has PAD, you might prioritize a GLP-1 receptor agonist, or specifically semaglutide, based on the results ...

Lilly competitor Novo Nordisk (NVO) has also experienced shortages of its GLP-1, semaglutide, marketed as Wegovy for weight loss and Ozempic for type 2 diabetes. That shortage is over as well.